Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
The Journal of Molecular Diagnostics : JMD|March 23, 2010
Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylationPhilipp Schatz, Dimo Dietrich, Thomas Koenig, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 14, 2006
Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasiaNeal K Osborn, Hongzhi Zou, Julian R Molina, et al.
Cell Death & Disease|March 31, 2017
Functional inhibition of acid sphingomyelinase by Fluphenazine triggers hypoxia-specific tumor cell deathSaskia Klutzny, Ralf Lesche, Matthias Keck, et al.
Breast Cancer Research and Treatment|September 18, 2007
The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical studyRastko Golouh, Tanja Cufer, Aleksander Sadikov, et al.
Journal of Translational Autoimmunity|April 5, 2021
An elevated polyclonal free light chain level reflects a strong interferon signature in patients with systemic autoimmune diseasesEléonore Bettacchioli, Christelle Le Gaffric, Margaux Mazeas, et al.
Development (Cambridge, England)|August 7, 2002
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary glandGang Li, Gertraud W Robinson, Ralf Lesche, et al.
Clinical Chemistry|December 20, 2007
DNA methylation biomarkers for blood-based colorectal cancer screeningCatherine Lofton-Day, Fabian Model, Theo Devos, et al.
Cancer Cell|March 7, 2003
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanismsDaniel J Freeman, Andrew G Li, Gang Wei, et al.
Clinical and Experimental Medicine|November 7, 2023
Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responsesSimon Heller, Sarah Glaeske, Katja Gluske, et al.
BMC Cancer|June 3, 2010
CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patientsDimo Dietrich, Manuel Krispin, Jörn Dietrich, et al.
Pageof 7